Welcome to our dedicated page for Baxter International news (Ticker: BAX), a resource for investors and traders seeking the latest updates and insights on Baxter International stock.
Baxter International Inc. (NYSE: BAX) is a global healthcare company dedicated to providing essential renal and hospital products. With a comprehensive portfolio that includes home, acute, and in-center dialysis, sterile IV solutions, infusion systems and devices, parenteral nutrition, biosurgery products, anesthetics, and pharmacy automation, Baxter plays a critical role in expanding access to healthcare worldwide.
Baxter's recent acquisition of Hillrom in late 2021 has significantly enhanced its hospital-focused offerings. This acquisition brought basic equipment like hospital beds under Baxter’s umbrella, along with advanced digital solutions such as smart beds and the Voalte medical communications app. These additions complement Baxter’s legacy operations, which focus on products for patients with acute and chronic kidney failure. Notably, Baxter plans to spin off its renal care segment by mid-2024.
Additionally, Baxter provides a variety of injectable therapies, including IV pumps, administrative sets, and nutritional products, as well as surgical sealants and hemostatic agents used in various care settings. The company’s extensive global footprint and the essential nature of its products and services underscore its commitment to advancing healthcare innovations and improving patient care in both emerging and developed markets.
Baxter’s financial condition remains robust, bolstered by its continuous innovation and strategic partnerships. The company’s employees worldwide are dedicated to building upon a rich heritage of medical breakthroughs, ensuring that Baxter continues to be at the forefront of healthcare advancements.
Baxter International Inc. (NYSE:BAX) will host a conference call on July 29, 2021, at 7:30 a.m. Central Time to discuss its Q2 2021 financial results. Participants can pre-register through a provided link. The call will also be available via webcast on Baxter's website. Baxter is recognized for its extensive portfolio of medical products that cater to critical care, nutrition, renal, hospital, and surgical needs, operating in over 100 countries for nearly 90 years.
Baxter International Inc. (NYSE:BAX) has released new data indicating that its Theranova hemodialysis (HDx) therapy may reduce cardiovascular events by 35% and hospitalization rates by 18% among Colombian dialysis patients. This study, presented at the 58th ERA-EDTA Congress, involved over 1,000 adult patients and suggests improved clinical outcomes for those using HDx therapy. The Theranova device, approved by the FDA, aims to filter a wider range of toxins, potentially reducing associated health risks.
Baxter International Inc. (NYSE:BAX) has launched Sharesource Analytics 1.0, a new digital health module for home-based peritoneal dialysis (PD) patients. This clinical management tool offers healthcare professionals a comprehensive dashboard for monitoring patient treatments over the last 180 days. The platform aims to improve patient adherence, catheter function, and reduce therapy dropout risks. Sharesource is already the leading home dialysis digital platform, managing over 25 million treatments in more than 70 countries, with plans for global rollout by subscription.
Baxter International Inc. (NYSE:BAX) launched PrisMax 2, enhancing continuous renal replacement therapy (CRRT) and organ support therapies for intensive care units (ICUs). This system includes features from the TrueVue digital health portfolio and the PrismaLung+ blood-gas exchanger for extracorporeal carbon dioxide removal (ECCO2R). Available in over 20 countries, PrisMax 2 emphasizes treatment accuracy, efficiency, and safety, developed from clinician feedback. The new system aims to optimize ICU care, especially post-COVID. A recent survey showed 77% of clinicians experience documentation overload.
Baxter International (NYSE:BAX) will present at the UBS Global Healthcare Virtual Conference on May 25, 2021, with CFO Jay Saccaro scheduled to speak at 2:00 p.m. Eastern Time. The presentation will be accessible via a live webcast on www.baxter.com, with a replay available until June 24, 2021.
Baxter, a leader in medical products, supports millions with its critical care, nutrition, renal, hospital, and surgical offerings, emphasizing its commitment to healthcare innovation worldwide.
Baxter International (NYSE:BAX) has announced a quarterly cash dividend increase to $0.28 per share, a 14% rise from the previous $0.245. The dividend is payable on July 1, 2021, to shareholders of record as of June 4, 2021, reflecting an annual rate of $1.12 per share. This marks the sixth consecutive year of quarterly dividend growth, underscoring Baxter's commitment to shareholder value amidst a global healthcare crisis, driven by a solid financial position.
Baxter International Inc. (NYSE:BAX) reported Q1 2021 results, with worldwide sales of approximately $2.9 billion, up 5%. U.S. sales decreased by 3% to $1.2 billion, while international sales rose 11% to $1.8 billion. Net income was $298 million, down 9%. The company emphasizes ongoing growth driven by its Acute Therapies and BioPharma Solutions units, supporting COVID-19 efforts. Notable achievements include FDA clearances for new products and strategic acquisitions to enhance its pharmaceuticals portfolio. For 2021, Baxter expects earnings of $2.85 to $2.93 per share and sales growth of 8-9%.
Baxter International Inc. (NYSE:BAX) has achieved recognition on the Global Inclusion Index across 11 countries, highlighting its commitment to diversity and inclusion. The countries recognized include Brazil, China, France, and others. This accolade, presented by Seramount, evaluates corporate efforts in promoting women and creating inclusive cultures. Baxter's leaders focus on advancing women into leadership roles, particularly in Europe. The company has received multiple diversity awards, consistently achieving high scores on equality indices, emphasizing its ongoing commitment to an inclusive workplace.
Baxter International Inc. (NYSE:BAX) has received a €1.5 million R&D grant from Germany's BMBF to develop a new technology platform for extracorporeal blood purification therapies. This initiative aims to enhance the selective removal of pathogenic substances while preserving essential blood components. Collaborating with Rapp Polymere GmbH, the project will focus on modifying biomaterials and coatings. Baxter aims to advance treatment options for patients suffering from acute conditions, maintaining its leadership in multi-organ support therapies.
Baxter International (NYSE:BAX) will present at the BofA Securities 2021 Virtual Health Care Conference on May 11, 2021, at 8:45 a.m. ET. CFO Jay Saccaro will lead the presentation, which can be accessed via a live webcast on Baxter's official website. The replay will be available until August 11, 2021. Baxter, with over 85 years in healthcare, delivers a wide range of critical care and surgical products globally, impacting millions of patients and caregivers each day.
FAQ
What is the current stock price of Baxter International (BAX)?
What is the market cap of Baxter International (BAX)?
What does Baxter International Inc. specialize in?
What was the impact of Baxter's acquisition of Hillrom?
What products does Baxter offer for kidney failure patients?
What are some of Baxter's injectable therapies?
What surgical products does Baxter provide?
What is Baxter's plan for its renal care segment?
How does Baxter contribute to global healthcare access?
How does Baxter ensure continuous innovation?
What are some of the digital solutions offered by Baxter?
What is Baxter's commitment to patient care?
